HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Profit from the Pros – Zacks Free Email Newsletter
Our free email newsletter is filled with timely stock picks and market commentary. Sign up for free. Already on board? Check out the archive.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive

BIIB: Biogen Idec Inc - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

BIOGEN IDEC INC (NASD)
BIIB 45.76 1.37 (3.09%) Vol.  8,636,818 15:59 ET

Day Low - High 44.11 - 46.47
52wk Low - High 37.21 - 55.34
Avg Volume 4,664,942
Industry MED-BIOMED/GENE
Market Cap 13.22 B
Div - Yield 0.00 - 0.00
PE (forward) 11.64
PEG Ratio 1.25
Current Year Est. 3.93
EPS Last Year 3.78
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
#1 Strong Buy 26.51%
#2 Buy 16.63%
#3 Hold 7.53%
#4 Sell 2.01%
#5 Strong Sell -0.07%
S&P 500 8.70%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 10/26/2009
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
BIOGEN IDEC INC BIIB PREMIUM
AETERNA ZENT-TS T.AEZ PREMIUM
MOMENTA PHARMA MNTA PREMIUM
VANDA PHARMACT VNDA PREMIUM
See all MED-BIOMED/GENE Peers

BROKERAGE RECOMMENDATIONS
Current ABR 2.90
ABR (Last Week) 2.90
# of Recs in ABR 27
Average Target Price 49.44
Industry Rank by ABR 50 out of 217
Rank in Industry 135 out of 173
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate BIIB?
Buy
Sell
Find out what the Zacks Community
thinks of BIIB at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR BIIB
Zacks Blog: Medicines Co. Misses & Cuts
Nov 02, 2009
Zacks Blog: FDA Approval for Glaxo Drug
Oct 28, 2009
Zacks Blog: BioMarin Purchases Huxley
Oct 27, 2009
Zacks Equity Research: Report for BIIB
Oct 26, 2009
Zacks Blog: Zacks Analyst Blog Highlights: Biogen Idec, Elan, UnitedHealth Group Inc., Forest Laboratories, Inc. and Cypress Biosciences
Oct 21, 2009
More Zacks Commentary
NEWS
Acorda Therapeutics (ACOR)
Nov 06, 2009
MMR Information Systems Engages Global Research Services as Advisorto Accelerate Time to Market for Anti-CD20 Monoclonal Antibodies
Nov 04, 2009
Trading Outlook for MannKind Corp. Issued by InvestorSoup.com
Nov 04, 2009
Facet Biotech Reports Third Quarter 2009 Financial Results
Nov 03, 2009
Biogen Idec (BIIB) NewsBite - BIIB Upgraded By Jefferies
Nov 02, 2009
More News
EARNINGS ESTIMATES
  This Quarter
12/2009
Next Quarter
03/2010
This Year
12/2009
Next Year
12/2010
Average Estimate 1.06 1.09 3.93 4.48
Number of Estimates 10 3 10 10
Low Estimates 0.99 1.04 3.86 4.12
High Estimate 1.12 1.15 4.00 4.85
Year Ago EPS 0.91 1.05 3.59 3.93
EPS Growth 16.37% 3.81% 9.55% 13.86%

More Estimates

COMPANY DESCRIPTION
IDEC Pharmaceuticals Corporation is a biopharmaceutical company engaged primarily in the research, development and commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases. Their first commercial product, Rituxan, and our most advanced product candidate, ZEVALIN, are for use in the treatment of certain B-cell non-Hodgkin's lymphomas. They are also developing products for the treatment of various autoimmune diseases (such as psoriasis, rheumatoid arthritis and lupus).

Full Company Report
FINANCIALS
EPS TTM 3.78
Sales 4097.51
Net Income 873.74
Price/Earnings 12.11
Price/Book 2
Price/Cash Flow 8.77
Price/Sales 3.06


More Financials

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research